Target intelligence / Profile preview

Alpha-amylase 2B (AMY2B)

Target
AMY2B
Molecular classification
Enzyme, Glycoside hydrolase (EC 3.2.1.1), Alpha-amylase family
01

Overview

Alpha-amylase 2B (AMY2B) is a pancreatic enzyme responsible for the initial hydrolysis of dietary starch and glycogen into maltose, maltotriose, and dextrins by cleaving internal 1,4-alpha-glucosidic bonds. It is secreted primarily by the pancreas into the small intestine and is crucial for normal carbohydrate digestion. AMY2B is one of several amylase isoenzymes in humans, distinct from salivary amylases, and encoded by the AMY2B gene on human chromosome 1. The protein consists of three domains (A, B, C), with the active site located in domain A and structural support from calcium binding in domain B. AMY2B is a clinical marker for pancreatic health, with altered levels often indicating pancreatic disease. Pharmacological inhibitors of alpha-amylase are used to slow carbohydrate digestion in metabolic diseases like diabetes mellitus.

Other names
Amylase alpha-2BPancreatic alpha-amylasePancreatic amylaseAMY2Alpha-amylase isoenzyme 2BAlpha-2B amylase
02

Mechanism of action

Competitive inhibition of alpha-amylase activity, reducing complex carbohydrate breakdown and slowing glucose absorption (for inhibitors like acarbose). Reduction of postprandial blood glucose rise.

03

Biological functions

Digestion of dietary starch and glycogen by hydrolyzing 1,4-alpha-glucosidic bondsCarbohydrate metabolismProduction of maltose, maltotriose, and alpha-limit dextrins from polysaccharides
04

Disease associations

Asthma (Occupational and environmentally induced)Possibly metabolic or digestive conditions (no strong evidence for major disease association beyond rare genetic deficiencies)
05

Safety considerations

Inhibition may cause gastrointestinal side effects, such as bloating, flatulence, and diarrhea (due to undigested carbohydrates passing to the colon)Deficiency may result in maldigestion of starches, but is rare
06

Interacting drugs

Acarbose (alpha-amylase inhibitor)

3 more in the full profile.

07

Biomarkers

Elevated or reduced pancreatic amylase levels in blood or urine can indicate pancreatic function or damage, including acute pancreatitis

Beyond the preview

Go deeper on Alpha-amylase 2B (AMY2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-amylase 2B (AMY2B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call